Comparison of ticagrelor and prasugrel just before PCI in NSTE
acute coronary syndromes, LIKE-ACCOAST analysis

a 2023

Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis

MOTOVSKA, Z., Jiří JARKOVSKÝ, A. KOVARIK, J. MROZEK, Ota HLINOMAZ et. al.

Základní údaje

Originální název

Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis

Autoři

MOTOVSKA, Z. (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), A. KOVARIK (203 Česká republika), J. MROZEK (203 Česká republika), Ota HLINOMAZ (203 Česká republika), J. PRECEK (203 Česká republika), M. HROMADKA (203 Česká republika), A. ZOHOR (203 Česká republika), Petr KALA (203 Česká republika, domácí), P. TOMASOV (203 Česká republika), P. CERVINKA (203 Česká republika), J. MATEJKA (203 Česká republika), Klára BENEŠOVÁ (203 Česká republika) a S. DRABKOVA (203 Česká republika)

Vydání

ESC Congress 2023 25-28 August 2023 Amsterdam, Netherlands, 2023

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 39.300 v roce 2022

Kód RIV

RIV/00216224:14110/23:00133231

Organizační jednotka

Lékařská fakulta

ISSN

DOI

http://dx.doi.org/10.1093/eurheartj/ehad655.1493

Klíčová slova česky

ticagrelor; NSTE ACS; prasugrel; acute coronary syndromes

Klíčová slova anglicky

ticagrelor; NSTE ACS; prasugrel; acute coronary syndromes

Štítky

FN KV, RIV, rivok, user, článek v časopise

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 2. 2024 13:41, Mgr. Tereza Miškechová

Anotace

V originále

Recommendations for the preference of prasugrel over ticagrelor just before PCI in NSTE ACS are based on limited and controversial evidence. Furthermore, prasugrel can’t be used in patients after a stroke/TIA, and the risk of bleeding in older and low-weight patients annuls its benefit. Purpose We aimed to add to the current evidence comparing the benefit of prasugrel and ticagrelor just before PCI (without pretreatment) in NSTE ACS patients.

Návaznosti

90249, velká výzkumná infrastruktura

Název: CZECRIN IV

Citovat

MOTOVSKA, Z., Jiří JARKOVSKÝ, A. KOVARIK, J. MROZEK, Ota HLINOMAZ, J. PRECEK, M. HROMADKA, A. ZOHOR, Petr KALA, P. TOMASOV, P. CERVINKA, J. MATEJKA, Klára BENEŠOVÁ a S. DRABKOVA. Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis. In ESC Congress 2023 25-28 August 2023 Amsterdam, Netherlands. 2023. ISSN 0195-668X. Dostupné z: https://dx.doi.org/10.1093/eurheartj/ehad655.1493.

@proceedings{2365651,
   author = {Motovska, Z. and Jarkovský, Jiří and Kovarik, A. and Mrozek, J. and Hlinomaz, Ota and Precek, J. and Hromadka, M. and Zohor, A. and Kala, Petr and Tomasov, P. and Cervinka, P. and Matejka, J. and Benešová, Klára and Drabkova, S.},
   booktitle = {ESC Congress 2023 25-28 August 2023 Amsterdam, Netherlands},
   doi = {http://dx.doi.org/10.1093/eurheartj/ehad655.1493},
   keywords = {ticagrelor; NSTE ACS; prasugrel; acute coronary syndromes},
   language = {eng},
   title = {Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis},
   url = {https://academic.oup.com/eurheartj/article/44/Supplement_2/ehad655.1493/7391067},
   year = {2023}
}

TY  - CONF
ID  - 2365651
AU  - Motovska, Z. - Jarkovský, Jiří - Kovarik, A. - Mrozek, J. - Hlinomaz, Ota - Precek, J. - Hromadka, M. - Zohor, A. - Kala, Petr - Tomasov, P. - Cervinka, P. - Matejka, J. - Benešová, Klára - Drabkova, S.
PY  - 2023
TI  - Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis
KW  - ticagrelor
KW  - NSTE ACS
KW  - prasugrel
KW  - acute coronary syndromes
UR  - https://academic.oup.com/eurheartj/article/44/Supplement_2/ehad655.1493/7391067
N2  - Recommendations for the preference of prasugrel over ticagrelor just before PCI in NSTE ACS are based on limited and controversial evidence. Furthermore, prasugrel can’t be used in patients after a stroke/TIA, and the risk of bleeding in older and low-weight patients annuls its benefit. Purpose We aimed to add to the current evidence comparing the benefit of prasugrel and ticagrelor just before PCI (without pretreatment) in NSTE ACS patients.
ER  -

MOTOVSKA, Z., Jiří JARKOVSKÝ, A. KOVARIK, J. MROZEK, Ota HLINOMAZ, J. PRECEK, M. HROMADKA, A. ZOHOR, Petr KALA, P. TOMASOV, P. CERVINKA, J. MATEJKA, Klára BENEŠOVÁ a S. DRABKOVA. Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis. In \textit{ESC Congress 2023 25-28 August 2023 Amsterdam, Netherlands}. 2023. ISSN~0195-668X. Dostupné z: https://dx.doi.org/10.1093/eurheartj/ehad655.1493.

Podrobný výpis o publikaci